High Altitude Clinical Trial
Official title:
Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude
Verified date | April 2021 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Ibuprofen is often taken by travelers to high altitude to treat the symptoms of acute mountain sickness such as headache and malaise. However, the blunting of inflammation by ibuprofen may slow the process of acclimatization to altitude, which relies on mediators of inflammation for adjustments in breathing. The study randomizes healthy subjects to receive ibuprofen or placebo and then ascend to altitude (12,500 feet). Blood cytokines and non-invasive measurements of blood and tissue oxygen levels will be made for 48 hours at altitude. The hypothesis being tested is that subjects receiving ibuprofen will have lower blood and tissue oxygen levels after 48 hours at altitude than will placebo subjects.
Status | Completed |
Enrollment | 20 |
Est. completion date | June 2017 |
Est. primary completion date | October 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - healthy subjects The group of subjects in this experiment will be composed of healthy adult volunteers, over age 18 and under age 65, of any ethnic group, in good physical and mental health. We expect to enroll approximately 20 subjects. The ethnic groups represented will depend on the ethnicity of those who wish to be subjects, but no ethnic groups will be specifically sought after or rejected. Exclusion Criteria: Subjects will be specifically excluded according to the following criteria: 1. History of any clinically significant medical condition, particularly abnormal respiratory, cardiovascular, neurological, hematological, renal or hepatic function. A medical history and physical exam will be performed at the screening session for each subject. We will use this to determine whether the subjects are healthy and without any history of these conditions. No laboratory workup will be required 2. Regular smokers (more than 1 cigarette or cigar per day). 3. Currently active or recently treated systemic or serious local infection. 4. Recent regular use of prescription medications or regular physician care for any significant medical condition. 5. A history of high altitude pulmonary edema or high altitude cerebral edema. 6. Recent exposure to altitude (>8000 ft) in the last month or having slept at an altitude >6000 feet in the last month. 7. Inability to provide written informed consent or to be able to complete the experiment. 8. Pregnancy as determined by a urine pregnancy test if subjects believe they might be pregnant 9. Allergy to non-steroid anti-inflammatory drugs (NSAIDs) or subjects reporting history or symptoms of ulcers or other ibuprofen related contraindications discussed with the screening physician. 10. Heavy coffee drinkers or caffeine users will be advised that they may suffer rebound headache when restricted from caffeinated beverages on measurement days, and asked to carefully consider any continuing participation in the study after abstaining from caffeine during their first sea level measurements. |
Country | Name | City | State |
---|---|---|---|
United States | White Mountain Research Center | Bishop | California |
United States | UCSF Hypoxia Research Laboratory | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | cerebral oximetry | non-invasive measurements of cerebral oxygenation with an FDA approved device | once daily for 2 days at sea level, on arrival at altitude and daily for 2 days | |
Other | acute mountain sickness inventory | standard questionnaire concerning symptoms associated with acute mountain sickness | once a day at both sea level (2 days) and altitude (2 days) | |
Primary | blood cytokine levels | venous blood sample, once a day | on days 1 and 2 at sea level, on arrival at altitude and daily for 2 days | |
Primary | cerebral blood flow | optical/non-invasive measure of frontal cortex cerebral blood flow with an FDA-approved device | once daily for 2 days at sea level, on arrival at altitude and once daily at altitude for 2 days | |
Secondary | pulse oximetry | finger pulse oximetry with an FDA approved pulse oximeter | once a day for 2 days at sea level, on arrival at altitude and daily for 2 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT06133530 -
Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica
|
N/A | |
Active, not recruiting |
NCT04604249 -
Prevalence of COVID-19 in High Altitude : Insights From the Highest City of the World
|
||
Not yet recruiting |
NCT05063643 -
Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
|
||
Recruiting |
NCT05474287 -
SJOV vs. HFNO for Hypoxia During Procedural Sedation at High Altitudes
|
N/A | |
Completed |
NCT06392373 -
High Altitude Muscle Recovery
|
N/A | |
Completed |
NCT03851744 -
High Altitude and Exogenous Carbohydrate Oxidation
|
N/A | |
Completed |
NCT01830530 -
HIGH Altitude CArdiovascular REsearch in the ANDES
|
Phase 4 | |
Completed |
NCT06164665 -
Effects of Pioglitazone on Exogenous Carbohydrate Oxidation During Steady-State Exercise at High Altitude
|
Phase 4 | |
Recruiting |
NCT06393998 -
CO2 Supplement for Treatment of Acute Mountain Sickness
|
N/A | |
Not yet recruiting |
NCT06446427 -
The Effect of Acute High Altitude Exposure on Rescuer Performance and Patient Care
|
N/A | |
Completed |
NCT04915378 -
Hypoxia-altitude Testing to Predict Altitude Related Adverse Health Effects in Chronic Obstructive Pulmonary Disease (COPD) Patients
|
||
Completed |
NCT04290481 -
Oxygen Saturation and Perfusion Index ın Neonates at High Altitude
|
||
Completed |
NCT05798416 -
Effect of Inhalation of Low Dose CO2 on Exercise Performance at High Altitude
|
N/A | |
Completed |
NCT05715476 -
The Effect of Different Altitude Levels on Spinal Anesthesia in Cesarean Section Surgery
|
N/A | |
Recruiting |
NCT05115721 -
Establishing the Reference Interval for Pulse Oxygen Saturation in Neonates at High Altitude
|
||
Recruiting |
NCT06152744 -
Evaluation of Membrane Lung Function in High-altitude Regions
|
||
Recruiting |
NCT05304923 -
Supraglottic Jet Oxygenation and Ventilation for Gastrointestinal Endoscopy at High-altitude
|
N/A | |
Recruiting |
NCT04199650 -
Definition of ARDS in Qinghai Province: Verification of Berlin Definition Plateau Criteria
|